www.fdanews.com/articles/83173-morphosys-enters-antibody-pact-with-u-s-merck
MORPHOSYS ENTERS ANTIBODY PACT WITH U.S. MERCK
December 15, 2005
MorphoSys has signed a licence agreement with U.S. drugmaker Merck & Co. Inc. (MRK.N: Quote, Profile, Research) for the use of MorphoSys's human therapeutic antibody technology, the German biotech firm said on Wednesday. As part of the five-year agreement for the use of MorphoSys's HuCAL GOLD and AutoCAL technologies, MorphoSys will receive an up-front payment, annual user fees and research and development funding, MorphoSys said in a statement.